Health · 1 sources covering this

STAT+: Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial

A next-gen Eli Lilly obesity drug led to bariatric-surgery levels of weight loss in a study, but also saw patients dropping out because of side effects.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·1h ago
STAT+: Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial
A next-gen Eli Lilly obesity drug led to bariatric-surgery levels of weight loss in a study, but also saw patients dropping out because of side effects.
Read at STAT →

STAT+: Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial

How 1 sources are covering this

STAT+: Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial

More from Health

COVID is shaping Americans' reaction to Ebola and hantavirus

Colorado Charts Its Own Course on Vaccines Amid Federal Pullback

ICE Arrests Are Separating Families. Here’s How To Plan Ahead.

Opinion: Living with bullet fragments in the body can have long-term medical consequences

Reader

Trust & legal

Across the network